What is the appropriate use of palliative docetaxel in castration-resistant prostate cancer?

References

• Lissbrant IF, Garmo H, Widmark A, Stattin P. Population-based study on use of chemotherapy in men with castration resistant prostate cancer. Acta Oncol Epub 2013;52: 1593–1601.
   PubMed Web of Science ®Google Scholar
• Holmberg LH. Can national cancer registration support clinical databases and clinical cancer research? Acta Oncol 2012;51:691–3.
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–12.
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr., Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513–20.
   PubMed Web of Science ®Google Scholar
• Fossa SD, Jacobsen AB, Ginman C, Jacobsen IN, Overn S, Iversen JR, et al. Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: A randomized phase II study. Eur Urol 2007;52: 1691–8.
   PubMed Web of Science ®Google Scholar
• Niraula S, Tannock IF. Broadening horizons in medical management of prostate cancer. Acta Oncol 2011;50(Suppl 1): 141–7.
   PubMed Web of Science ®Google Scholar
• Graf W, Glimelius B, Påhlman L, Bergström R. The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer. Br J Cancer 1994;70: 559–63.
   PubMed Web of Science ®Google Scholar
• Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: A meta-analysis. Meta-analysis group in cancer. Lancet 2000;356:373–8.
   PubMed Web of Science ®Google Scholar
• Weeks JC, Catalano PJ, Cronin A, Finkelman MD, Mack JW, Keating NL, et al. Patients’ expectations about effects of chemotherapy for advanced cancer. N Engl J Med 2012; 367:1616–25.
   PubMed Web of Science ®Google Scholar
• Magarotto R, Lunardi G, Coati F, Cassandrini P, Picece V, Ferrighi S, et al. Reduced use of chemotherapy at the end of life in an integrated-care model of oncology and palliative care. Tumori 2011;97:573–7.
   PubMed Web of Science ®Google Scholar
• Sorbye H, Pfeiffer P, Cavalli-Bjorkman N, Qvortrup C, Holsen MH, Wentzel-Larsen T, et al. Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. Cancer 2009;115:4679–87.
   PubMed Web of Science ®Google Scholar
• van der Pool AE, Damhuis RA, Ijzermans JN, de Wilt JH, Eggermont AM, Kranse R, et al. Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: A population-based series. Colorectal Dis 2012;14:56–61.
   PubMed Web of Science ®Google Scholar
• Cavalli-Bjorkman N, Qvortrup C, Sebjornsen S, Pfeiffer P, Wentzel-Larsen T, Glimelius B, et al. Lower treatment intensity and poorer survival in metastatic colorectal cancer patients who live alone. Br J Cancer 2012;107:189–94.
   PubMed Web of Science ®Google Scholar
• Randen M, Helde-Frankling M, Runesdotter S, Strang P. Treatment decisions and discontinuation of palliative chemotherapy near the end-of-life, in relation to socioeconomic variables. Acta Oncol 2013;52:1062–6.
   PubMed Web of Science ®Google Scholar
• Nappa U, Lindqvist O, Rasmussen BH, Axelsson B. Palliative chemotherapy during the last month of life. Ann Oncol 2011;22:2375–80.
   PubMed Web of Science ®Google Scholar
• Liu TW, Chang WC, Wang HM, Chen JS, Koong SL, Hsiao SC, et al. Use of chemotherapy at the end of life among Taiwanese cancer decedents, 2001–2006. Acta Oncol 2012;51:505–11.
   PubMed Web of Science ®Google Scholar
• Glare P, Virik K, Jones M, Hudson M, Eychmuller S, Simes J, et al. A systematic review of physicians’ survival predictions in terminally ill cancer patients. Br Med J 2003;327:195–8.
   PubMed Web of Science ®Google Scholar
• Ullen A, Shah CH, Kirkali Z. Management of advanced prostate cancer – new drugs. Acta Oncol 2011;50(Suppl 1): 137–40.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13:983–92.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368: 138–48.
   PubMed Web of Science ®Google Scholar
• Denis LJ, Roobol M, Dourcy-Belle-Rose B. Prostate cancer from the horizon of the patient. Acta Oncol 2011;50(Suppl 1): 148–54.
   PubMed Web of Science ®Google Scholar